Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise

Arovella Therapeutics (ASX:ALA) has received firm commitments from institutional and sophisticated investors to raise about AU$12.5 million via a placement of 125 million new fully paid ordinary share

MT NewswiresMar 25 21:50 ET

While Shareholders of Arovella Therapeutics (ASX:ALA) Are in the Black Over 1 Year, Those Who Bought a Week Ago Aren't so Fortunate

Yahoo FinanceMar 20 16:34 ET

Arovella Therapeutics' ALA-101-onCARlytics Collaboration With Imugene Ends; Shares Down 12%

Arovella Therapeutics (ASX:ALA) said its collaboration with Imugene (ASX:IMU) to combine ALA‐101 and onCARlytics has ended, effective immediately, according to a Wednesday filing with the Australian S

MT NewswiresMar 19 20:39 ET

Arovella Boosts Solid Tumor Pipeline With Novel CAR-iNKT Cell Armouring Tech License

Arovella Therapeutics (ASX:ALA) secured an exclusive license from the University of North Carolina Lineberger Comprehensive Cancer Center to integrate cytokine technology into its CAR-iNKT cell platfo

MT NewswiresJan 30 05:46 ET

Arovella Therapeutics Well-placed to Advance INKT Cell Therapy Cancer Treatment Towards First-in-human Clinical Trials

Arovella Therapeutics Ltd (ASX:ALA) capped off the December quarter in a “solid financial position” with pro-forma cash and cash equivalents of $4.76 million to continue advancing its iNKT cell therapy platform for cancer treatment towards first-in-human clinical trials.

Investing.com Jan 24 23:12 ET

Arovella Therapeutics Manufactures GMP-Grade Lentiviral Vector for Cancer Therapy Product; Shares Climb 4%

Biotechnology company Arovella Therapeutics (ASX:ALA) said Tuesday that the manufacturing of the good manufacturing practice (GMP)‐grade lentiviral vector for its lead product, ALA‐101, has been compl

MT NewswiresJan 1 21:37 ET